- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03018938
A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus (CLASSIC)
Comparison Between Basal Insulin Analog and Insulin Analog Mid Mixture AS Starter Insulin for Chinese Patients With Type 2 Diabetes Mellitus (CLASSIC Study)
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
-
Beijing, China, 102206
- Peking University International Hospital
-
Beijing, China
- Beijing Hai Dian Hospital
-
Shanghai, China, 200090
- Shanghai Yangpu District Central Hospital
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Peking University Peoples Hospital
-
Beijing, Beijing, China, 100016
- Beijing Huaxin Hospital
-
Chaoyang, Beijing, China, 100028
- China Meitan General Hospital
-
Fangshan, Beijing, China, 102500
- Beijing Yanhua Hospital
-
-
Gansu
-
Lanzhou, Gansu, China, 730030
- The 2nd Hospital of Lanzhou University
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518020
- Shenzhen City People Hospital
-
Yuexiu, Guangdong, China, 510080
- The 1st Hospital with Guangdong Pharmaceutical University
-
-
Henan
-
Luoyang, Henan, China, 471003
- The 1st Affiliated Hospital of Henan Science and technology
-
Zhengzhou, Henan, China, 450003
- People's Hospital of Henan Province
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Wuhan Union (Xiehe) Hospital
-
-
Jiangsu
-
Changzhou, Jiangsu, China, 213003
- Changzhou No.2 People's Hospital
-
Nanjing, Jiangsu, China, 210001
- Nanjing TCM hospital
-
Nanjing, Jiangsu, China, 210024
- Jiang Su Province Official Hospital
-
Nanjing, Jiangsu, China, 210048
- Nanjing Jiangbei Hospital
-
Nanjing, Jiangsu, China, 211100
- Nanjing Jiangning Hospital
-
Taizhou, Jiangsu, China, 225300
- Taizhou City People Hospital
-
Wuxi, Jiangsu, China, 214000
- The Second People's Hospital of Wuxi
-
Xuzhou, Jiangsu, China, 221009
- Xuzhou Central Hospital
-
-
Shandong
-
Qingdao, Shandong, China, 266071
- Qingdao Municipal Hospital
-
Taian, Shandong, China, 271000
- Taian City Central Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200135
- Shanghai Pudong New Area Gongli Hospital
-
Shanghai, Shanghai, China, 201318
- Shanghai Pudong New District Zhoupu Hospital
-
-
Shunqing
-
Nanchong, Shunqing, China, 637000
- Affiliated Hospital of North Sichuan Medical College
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- The Third Affiliated Hospital of Chengdu University of TCM
-
Luzhou, Sichuan, China, 646000
- Southwest Medical University Affiliated Hospital
-
-
Tianjin
-
Nankai, Tianjin, China, 300192
- Tianjin First Central Hospital
-
-
Tongzhou
-
Beijing, Tongzhou, China, 101149
- Beijing Luhe Hospital Capital Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310014
- Zhejiang Provincial People's Hospital
-
Ningbo, Zhejiang, China, 315010
- Ningbo First Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- have type 2 diabetes as defined by World Health Organization (WHO) criteria
- are taking oral anti-hyperglycemic medications (OAMs) and are judged as OAM failure by the investigator
- most recent HbA1c value ≥7.5% within 12 weeks of study entry
- in the opinion of the investigator, require to initiate premix analog or basal insulin analog treatment
- willing to start with insulin treatment
Exclusion Criteria:
- have a diagnosis of type 1 diabetes
- have received any type of insulin within 24 months of study entry (except for intermittent use of insulin of less than 1 month each time)
- have serious preexisting medical or other conditions that, in the judgment of the investigator, would preclude participation in this study
- are pregnant or breastfeeding, or intend to become pregnant during the course of the study
- are currently enrolled or have participated, within the last 30 days in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Insulin Analog Mid Mixture
Insulin analog mid mixture given subcutaneously (SC).
|
Administered SC
|
Experimenteel: Basal Insulin Analog
Basal insulin analog given SC.
|
Administered SC
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)
Tijdsspanne: Baseline, 24 Weeks
|
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by analysis of covariance (ANCOVA) model with last observation carried forward (LOCF) and with terms for change from baseline in HbA1c as response, treatment as fixed effect and baseline HbA1c as covariate. |
Baseline, 24 Weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change From Baseline to Week 48 in HbA1c
Tijdsspanne: Baseline, 48 Weeks
|
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by ANCOVA model with LOCF and with terms for change from baseline in HbA1c as response, treatment as fixed effect and baseline HbA1c as covariate. |
Baseline, 48 Weeks
|
Percentage of Participants Who Achieve HbA1c <7% at Week 24
Tijdsspanne: 24 Weeks
|
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
|
24 Weeks
|
Percentage of Participants Who Achieve HbA1c <7% at Week 48
Tijdsspanne: 48 Weeks
|
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
|
48 Weeks
|
Change From Baseline to Week 24 in Venous Fasting Plasma Glucose
Tijdsspanne: Baseline, 24 Weeks
|
Fasting Plasma glucose (FPG) is a test to determine how much glucose (sugar) is in a plasma sample after an overnight fast.
Least Squares (LS) means was determined by ANCOVA model with LOCF and with terms for change from baseline in Venous FPG as response, treatment as fixed effect and baseline Venous FPG as covariate.
|
Baseline, 24 Weeks
|
Change From Baseline to Week 48 in Venous Fasting Plasma Glucose
Tijdsspanne: Baseline, 48 Weeks
|
Fasting Plasma glucose (FPG) is a test to determine how much glucose (sugar) is in a plasma sample after an overnight fast.
Least Squares (LS) means was determined by ANCOVA model with LOCF and with terms for change from baseline in Venous FPG as response, treatment as fixed effect and baseline Venous FPG as covariate.
|
Baseline, 48 Weeks
|
Change From Baseline to Week 24 in Finger Stick Blood Glucose (FSBG)-Based Fasting Blood Glucose, Post Prandial Glucose
Tijdsspanne: Baseline, 24 Weeks
|
Fasting blood glucose (FBG) and post prandial glucose (PPG) [pre-breakfast (fasting) and post-breakfast (approximately 2 hours after breakfast)] was measured using FSBG.
LS Mean was measured with ANCOVA model with LOCF and with terms for change from baseline in FSBG-based FBG/PPG as response, treatment as fixed effect and baseline FSBG-based FBG/PPG as covariate.
|
Baseline, 24 Weeks
|
Change From Baseline to Week 48 in Finger Stick Blood Glucose (FSBG)-Based Fasting Blood Glucose, Post Prandial Glucose
Tijdsspanne: Baseline, 48 Weeks
|
Fasting blood glucose (FBG) and post prandial glucose (PPG) [pre-breakfast (fasting) and post-breakfast (approximately 2 hours after breakfast)] was measured using FSBG.
LS Mean was measured with ANCOVA model with LOCF and with terms for change from baseline in FSBG-based FBG/PPG as response, treatment as fixed effect and baseline FSBG-based FBG/PPG as covariate.
|
Baseline, 48 Weeks
|
Total Daily Insulin Dose at Week 24 and 48
Tijdsspanne: 24 Weeks, 48 Weeks
|
Total daily insulin dose in the basal insulin analog and in Insulin Analog Mid Mixture group at week 24 and 48.
|
24 Weeks, 48 Weeks
|
Change From Baseline to Week 24 in Body Weight
Tijdsspanne: Baseline, 24 Weeks
|
LS means were calculated using ANCOVA model with LOCF and with terms for change from baseline in bodyweight as response, treatment as fixed effect and baseline bodyweight as covariate.
|
Baseline, 24 Weeks
|
Change From Baseline to Week 48 in Body Weight
Tijdsspanne: Baseline, 48 Weeks
|
LS means were calculated using ANCOVA model with LOCF and with terms for change from baseline in bodyweight as response, treatment as fixed effect and baseline bodyweight as covariate.
|
Baseline, 48 Weeks
|
Rate of Hypoglycemia at Week 24 and 48
Tijdsspanne: 24 Weeks, 48 Weeks
|
Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of ≤70 mg/dL (3.9 mmol/L).
The overall yearly rates (events/participant/year) of those hypoglycemic events, calculated as, for each participant, the number of episodes times 365.25 and then divided by the participants treatment duration, will be summarized, and analyzed by a Negative-binomial regression model with treatment as fixed effects and log of (patient's treatment duration/365.25)
as an offset variable.
|
24 Weeks, 48 Weeks
|
Number of Participants With Insulin Treatment Change at Week 48
Tijdsspanne: Baseline through 48 Weeks
|
Insulin treatment change can be insulin treatment discontinuation, switch, intensification or reduction in frequency.
|
Baseline through 48 Weeks
|
Percentage of Participants Who Achieve the HbA1c <7% Without Switching and Discontinuing Study Insulin, and Without Using Rescue Therapy at Week 24
Tijdsspanne: 24 Weeks
|
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Percentages of participants who achieved HbA1c levels of <7% were analyzed using a logistic regression model with logic link function, treatment as fixed effect and baseline HbA1c as continuous covariate.
|
24 Weeks
|
Percentage of Participants Who Achieve the HbA1c <7% Without Switching and Discontinuing Study Insulin, and Without Using Rescue Therapy at Week 48
Tijdsspanne: 48 Weeks
|
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Percentages of participants who achieved HbA1c levels of <7% were analyzed using a logistic regression model with logic link function, treatment as fixed effect and baseline HbA1c as continuous covariate.
|
48 Weeks
|
Change From Baseline to Week 48 in Self-Efficacy About Insulin Therapy Questionnaire (SEITQ) Score
Tijdsspanne: Baseline, 48 Weeks
|
The SEITQ is designed to measure an individual's self-efficacy related to insulin therapy.
The SEITQ consists of 5 items (that is, statements).
The first 4 statements imply confidence in completing the tasks needed to take insulin correctly and avoid both hyperglycemia and hypoglycemia, whereas the last statement is an outcome expectation and implies that performance of these tasks will lead to avoidance of complications.
Each item score ranges from 1 (strongly disagree) to 7 (strongly agree).
The total SEITQ score is the sum of each item scores, with the range of 5 to 35.
Higher SEITQ score indicates better outcome (higher self-efficacy).
LS Mean was calculated using Mixed Models Analysis (MMRM) for repeated measures with all post-baseline SEITQ as responses, baseline SEITQ as a continuous covariate, treatment group, Visits, and treatment by visit interaction as fixed effects and participant as a random effect.
|
Baseline, 48 Weeks
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 16507
- F3Z-GH-IOQR (Andere identificatie: Eli Lilly and Company)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Diabetes mellitus type 2
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationWervingDiabetes mellitus type 2 met complicatiesIndië
-
SanofiVoltooidDiabetes mellitus type 1 - Diabetes mellitus type 2Hongarije, Russische Federatie, Duitsland, Polen, Japan, Verenigde Staten, Finland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...Voltooid
-
AstraZenecaWerving
-
Daewoong Pharmaceutical Co. LTD.Nog niet aan het wervenT2DM (diabetes mellitus type 2)
-
Zhongda HospitalWervingDiabetes mellitus type 2 (T2DM)China
-
Newsoara Biopharma Co., Ltd.WervingT2DM (diabetes mellitus type 2)China
-
Shanghai Golden Leaf MedTec Co. LtdActief, niet wervendDiabetes mellitus type 2 (T2DM)China
-
SanofiVoltooid
-
Haisco Pharmaceutical Group Co., Ltd.VoltooidT2DM (diabetes mellitus type 2)China